Adamis Pharmaceuticals (NASDAQ:ADMP) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a research report issued on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Stock Down 23.8 %

Shares of ADMP opened at $0.17 on Thursday. The stock’s fifty day simple moving average is $0.21 and its 200 day simple moving average is $0.22. Adamis Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $0.70.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Adamis Pharmaceuticals stock. State Street Corp raised its stake in Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Get Rating) by 13.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 475,373 shares of the specialty pharmaceutical company’s stock after purchasing an additional 55,168 shares during the quarter. State Street Corp owned about 0.32% of Adamis Pharmaceuticals worth $271,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.57% of the company’s stock.

About Adamis Pharmaceuticals

(Get Rating)

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.